Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 8/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.42 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13396793 | 0.93 | P2RY12 (0.42) | P2RY12PRMT6ADORA2AADORA2B | |
| SCHEMBL25496737 | 0.92 | P2RY12 (0.43) | P2RY12PRMT6BMPR1B | |
| SCHEMBL25496179 | 0.90 | P2RY12 (0.44) | P2RY12PRMT6ADORA2AADORA2BBMPR1B | |
| SCHEMBL13964754 | 0.86 | ADORA2A (0.52) | P2RY12ADORA2AADORA2B | |
| SCHEMBL14102400 | 0.85 | P2RY12 (0.47) | P2RY12ADORA2AADORA2BBMPR1B | |
| SCHEMBL3320995 | 0.85 | P2RY12 (0.47) | P2RY12ADORA2AADORA2BBMPR1B | |
| SCHEMBL3320975 | 0.85 | P2RY12 (0.47) | P2RY12ADORA2AADORA2BBMPR1B | |
| SCHEMBL30580422 | 0.83 | P2RY12 (0.46) | P2RY12ADORA2AADORA2BBMPR1B | |
| SCHEMBL20149801 | 0.82 | PRMT6 (0.49) | P2RY12PRMT6BMPR1B | |
| SCHEMBL20149806 | 0.82 | ADORA1 (0.53) | P2RY12ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230146410-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH INC (US) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230146410-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | STING1, CGAS, MAVS | P2RY12 220/4885PRMT6 1213/4885ADORA2A 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.